Rituximab-induced serum sickness and anaphylaxis in a child with nephrotic syndrome

Creative Commons License

TORUN BAYRAM M., SOYLU A., KAVUKÇU S.

TURKISH JOURNAL OF PEDIATRICS, vol.62, no.5, pp.884-888, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 62 Issue: 5
  • Publication Date: 2020
  • Doi Number: 10.24953/turkjped.2020.05.025
  • Journal Name: TURKISH JOURNAL OF PEDIATRICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.884-888
  • Keywords: rituximab, nephrotic syndrome, serum sickness, anaphylaxis, ONSET, INFUSION, RISK
  • Dokuz Eylül University Affiliated: Yes

Abstract

Background. Rituximab is effective for treatment of children with refractory nephrotic syndrome (NS). However, the drug may cause serum sickness characterized by fever, rash, and arthralgia 10-14 days after primary antigen exposure or within a few days after secondary antigen exposure. Rituximab may also lead to anaphylaxis. It is important to recognize rituximab-induced serum sickness (RISS) clinically, as it may mimic various infectious or vasculitic diseases.